Skip to the content
logo mainlogo darklogo light
logo main
logo main
  • Home
  • Team
  • Pipeline
  • Science
  • News
  • CONTACT
June 18, 2026
NEWS

AATec to Present Data from Lead Candidate ATL-105 at World Bronchiectasis Conference 2026

· Preclinical data demonstrate ATL-105’s multimodal effects for the treatment of non-CF bronchiectasis, including broad activity against key disease drivers such as neutrophil s

Read More
by philipp
August 14, 2025
NEWS

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Diseases

· Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin · Lead indication is non-CF bronchiectasis; ATL-105 targe

Read More
by philipp
April 15, 2025
NEWS

AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development

Funding from SPRIND and Family Offices accelerates preparation of ATL-105 for clinical development in lead indication non-CF related bronchiectasis by 2026 Munich, Germany – 15.0

Read More
by philipp
September 18, 2024
NEWS

AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board

Leading Expert in Respiratory Medicine Supporting AATec in Product Development in Non-CF Bronchiectasis Munich, Germany – 18.09.2024 – AATec Medical GmbH (AATec), a biotech com

Read More
by philipp
July 17, 2023
NEWS

AATec Medical Announces its Launch with EUR 2.7 million in Seed Financing to Unlock the Therapeutic Potential of Alpha-1 Antitrypsin

GO BACK TO NEWS

Read More
by mcservices

2024 | Copyright ©AATec Medical GmbH

  • Imprint
  • Privacy Policy

  • HomeHome
  • TeamTeam
  • PipelinePipeline
  • ScienceScience
  • NewsNews
  • CONTACTCONTACT

Follow us on

A Versatile Platform for Global Respiratory Health

Beyond NCFB, our recombinant AAT platform offers significant potential in major respiratory markets like COPD and asthma, where it targets underserved neutrophilic inflammation. It also offers significant potential in airway infections, leveraging ATL-105’s antiviral and bacteriostatic effects to reduce exacerbations. In the long-term our AAT products could help close critical care gaps in pulmonary indications including acute respiratory distress syndrome (ARDS) and bronchiolitis obliterans syndrome (BOS).

Non-CF Bronchiectasis (NCFB)

Our lead indication non-cystic fibrosis bronchiectasis (NCFB) is a debilitating chronic respiratory disease marked by permanent airway enlargement and a “vicious vortex” of persistent neutrophilic inflammation and recurrent infections.

Despite its severity, there are currently treatment options are still limited for the over 3 million patients in Western countries alone. This represents a massive unment medical need and a significant market opportunity, with a peak sales potential of $1.8 billion for ATL-105 in this indication alone.

ATL-105 provides a compelling biological rationale for the treatment of NCFB, as its multimodal action directly targets the underlying drivers of tissue destruction by irreversibly inhibiting neutrophil proteases, restoring the airway’s cytokine balance.